Bristol Myers Squibb Confirms Sale of 60% Stake in Sino-American Shanghai Squibb Pharmaceuticals

Bristol-Myers Squibb stated that the company's firm commitment to the Chinese market remains unchanged, and it will continue to invest in the Chinese market under the guidance of its "China 2030 Strategy."

On the evening of September 15, a reporter from Yicai confirmed with Bristol-Myers Squibb that the company has signed an agreement to sell its 60% stake in Sino-American Shanghai Squibb Pharmaceuticals Ltd. Bristol-Myers Squibb stated that its firm commitment to the Chinese market remains unchanged, and it will continue to invest in China under the guidance of the company's "China 2030 Strategy." In the future, the company will remain dedicated to accelerating the introduction of innovative cutting-edge therapies across a wide range of disease areas and fully enhancing drug accessibility. (Yicai reporter Zhiying Lin)